ArticleMethodsX2026
A practical approach to a single-chain variable fragment (scFv) biotinylating for immunohistochemical analysis.
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunohistochemistry (IHC) is a widely used technique for detecting proteins in tissue sections; however, its performance is significantly influenced by the quality of antibodies and detection strategies. Conventional IgG or IgM-based antibodies often come with high production costs, variability between batches, and limited penetration into tissues, which can compromise the uniformity and reproducibility of staining. Recombinant single-chain variable fragments (scFvs) offer an attractive alternative due to their smaller size, defined molecular composition, and renewable production capabilities. In this work, we focus on optimizing IHC by chemically biotinylating scFvs, allowing for direct coupling to streptavidin-based detection systems. This method enhances signal sensitivity while eliminating the need for secondary antibodies or additional labeling steps. Biotinylated scFvs can diffuse more easily into tissue sections, streamline the staining workflow, and reduce both assay time and cost. Overall, integrating biotinylated scFvs into IHC protocols presents a robust, scalable, and reproducible strategy that addresses key limitations of conventional antibody-based methods, thus supporting more consistent and efficient protein detection in histological analyses.This protocol allowed the optimization of conventional IHC conditions by using biotinylating scFv to achieve precise, time and cost-efficient antigen visualization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.